- Home
- OSTX vs SLS Comparison
OSTX vs SLS Comparison
Compare OSTX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- SLS
- Stock Information
- Founded
- OSTX 2018
- SLS 2012
- Country
- OSTX United States
- SLS United States
- Employees
- OSTX N/A
- SLS N/A
- Industry
- OSTX
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- OSTX
- SLS Health Care
- Exchange
- OSTX NYSE
- SLS Nasdaq
- Market Cap
- OSTX 86.5M
- SLS 75.3M
- IPO Year
- OSTX 2024
- SLS N/A
- Fundamental
- Price
- OSTX $4.61
- SLS $0.90
- Analyst Decision
- OSTX Strong Buy
- SLS
- Analyst Count
- OSTX 2
- SLS 0
- Target Price
- OSTX $14.50
- SLS N/A
- AVG Volume (30 Days)
- OSTX 72.8K
- SLS 1.6M
- Earning Date
- OSTX 11-15-2024
- SLS 11-13-2024
- Dividend Yield
- OSTX N/A
- SLS N/A
- EPS Growth
- OSTX N/A
- SLS N/A
- EPS
- OSTX N/A
- SLS N/A
- Revenue
- OSTX N/A
- SLS N/A
- Revenue This Year
- OSTX N/A
- SLS N/A
- Revenue Next Year
- OSTX $9,900.00
- SLS N/A
- P/E Ratio
- OSTX N/A
- SLS N/A
- Revenue Growth
- OSTX N/A
- SLS N/A
- 52 Week Low
- OSTX $1.58
- SLS $0.50
- 52 Week High
- OSTX $5.46
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- SLS 30.01
- Support Level
- OSTX N/A
- SLS $0.86
- Resistance Level
- OSTX N/A
- SLS $0.98
- Average True Range (ATR)
- OSTX 0.00
- SLS 0.11
- MACD
- OSTX 0.00
- SLS -0.02
- Stochastic Oscillator
- OSTX 0.00
- SLS 21.74
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.